14% af de patienter, der er behandlet med CRIXIVAN alene eller i kombination med andre antiretrovirale stoffer, er der set isoleret, asymptomatisk hyperbilirubinæmi (totalbilirubin ≥2, 5 mg/ dl, 43 µmol/ l), der overvejende er indberettet som forhøjet indirekte bilirubin og sjældent associeret med stigninger i ALAT, ASAT eller alkalisk phosphatase.
Hepato-biliary disorders: isolated asymptomatic hyperbilirubinaemia (total bilirubin ≥ 2.5 mg/ dl, 43 mcmol/ l), reported predominantly as elevated indirect bilirubin and rarely associated with elevations in ALT, AST, or alkaline phosphatase, has occurred in approximately 14% of patients treated with CRIXIVAN alone or in combination with other antiretroviral agents.